Our study provides insight into the possible role of gut microbiota-derived secondary metabolites, such as UDCA, as an anti-cancer therapeutics that can act as a molecular switch dictating SOCS1 functionality towards tumor suppression by regulating inflammation and, in the long run, inflammation-driven colon cancer. This evidence concerns the gene SOCS1 and colonic neoplasm.